ANGPTL3 Inhibitors
1 drugsAbout ANGPTL3
ANGPTL3 is a secreted protein that inhibits lipoprotein lipase (LPL) and endothelial lipase, key enzymes in lipid metabolism. By inhibiting these lipases, ANGPTL3 influences triglyceride and cholesterol levels in the blood.
ANGPTL3 is a therapeutic target for metabolic disorders, though currently there is no genetic evidence available linking it to specific diseases. The existence of an approved drug, EVKEEZA, underscores the therapeutic potential of modulating ANGPTL3 activity.
ANGPTL3 is targeted by one FDA-approved biologic drug, EVKEEZA (Regeneron), approved in 2021. This positions ANGPTL3 as a relatively new target in the metabolic disease space.
Top ANGPTL3 Drugs
Regeneron is the only company with an approved drug targeting ANGPTL3.
The market is highly concentrated, suggesting high barriers to entry or a first-mover advantage for Regeneron.
ANGPTL3 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ANGPTL3, using biologic (other) modality.
The lack of small molecule or other modalities represents a whitespace opportunity for novel therapeutic development.
ANGPTL3 Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ANGPTL3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 1 | 1 | 67% |
| Phase 3 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ANGPTL3 Drug Approval Timeline (2021 - 2021)
The first and only drug targeting ANGPTL3, EVKEEZA, was approved in 2021.
The recent approval suggests a growing interest in ANGPTL3 as a target, but also indicates a potentially unsaturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ANGPTL3. A trial counts if an approved drug acting on ANGPTL3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.